Daily Literature Update
Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
Katoh N, Tanaka A, Takahashi H, et al. Curr Med Res Opin. 2025 Jan;41(1):1-12. PMID: 39625230.
Introduction
Lebrikizumab combined with topical corticosteroids shows promise for moderate-to-severe atopic dermatitis, addressing significant unmet needs in Japanese patients.
Study Overview
Study Type: Phase 3, randomized, double-blind, placebo-controlled trial
Population: 286 Japanese patients aged ≥12 years, moderate-to-severe AD
Intervention: Lebrikizumab 250 mg Q4W or Q2W plus topical corticosteroids
Outcomes: IGA 0/1 with ≥2-point improvement, EASI 75 at 16 weeks
Key Findings
- IGA responders: 29.1% (Q4W), 33.4% (Q2W) vs 6.1% placebo (p < 0.001)
- EASI 75 achievement: 47.2% (Q4W), 51.2% (Q2W) vs 13.4% placebo (p < 0.001)
- Serious AEs: 2.4% placebo, 0% Q4W, 0.8% Q2W
- Common AEs: pyrexia, allergic conjunctivitis, conjunctivitis – mostly mild/moderate
Context & Related Research
- Simpson et al., 2023: Lebrikizumab+TCS improved moderate-to-severe AD outcomes; safe with manageable conjunctivitis (PMID:36630140).
- Silverberg et al., 2023: Two phase 3 monotherapy trials showed >50% EASI 75 rates; mild conjunctivitis common (PMID:36920778).
- Gold et al., 2023: Integrated safety analysis of 1720 patients confirmed good tolerability; conjunctivitis incidence consistent (PMID:37195407).
- Katoh et al., 2025: Current Japanese phase 3 trial confirms efficacy and safety of lebrikizumab+TCS (PMID:39625230).
Clinical Implications
- Lebrikizumab+TCS provides significant skin clearance benefits in moderate-to-severe AD.
- Favorable safety profile, but conjunctivitis requires awareness and monitoring.
- Supports expanding use in patients inadequately controlled by topical therapy alone.
Strengths & Limitations
| Strengths | Limitations |
|---|---|
| Randomized, placebo-controlled multicenter design | Short 16-week induction period; longer data needed |
| Ethnically specific Japanese population enhancing regional relevance | Limited generalizability beyond Japanese patients |
| Clinically relevant endpoints (IGA, EASI 75) | No active comparator; indirect efficacy comparisons only |
Conclusion
Lebrikizumab combined with topical corticosteroids shows significant clinical efficacy and favorable safety for moderate-to-severe atopic dermatitis in Japanese patients.
Listen to the Podcast
A short discussion of today’s highlight.
Future Directions
Long-term durability and safety beyond 16 weeks and deeper understanding of conjunctivitis mechanisms are needed for optimized clinical use.
